Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-07-2021 | COVID-19 | Retinal Disorders

Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity

Authors: Lydia G. Stone, Michael E. Grinton, James S. Talks

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 7/2021

Abstract

Purpose

The coronavirus pandemic has prompted unprecedented delays to treatment with anti-VEGF intravitreal injections due to the need to reduce hospital attendances and prioritise the patients at highest risk of vision loss. This study aims to quantify the effect of these delays on visual acuity (VA) outcomes and optical coherence tomography (OCT) features for patients receiving treatment for neovascular age-related macular degeneration (nAMD), retinal vein occlusions (RVO) and diabetic macular oedema (DMO) and correlate to the Royal College of Ophthalmologists guidelines (RCOphth).

Methods

A retrospective data analysis of an electronic medical record was performed on a random sample of eyes receiving anti-VEGF injections for nAMD, RVO or DMO. Data collected included age, sex, reason for injection, number of weeks delay if > 8 weeks from that planned, VA at baseline and follow-up and the OCT features, if delayed. For those eyes not delayed, a visual acuity at 20 weeks was recorded to provide a control group.

Results

A sample of 981 eyes (858 patients) were analysed. There was a delay in review of 8 weeks or more in 39.6% of patients of which 30.4% had since returned for review (28.4% nAMD, 37.6% RVO and 30.0% DMO). There was no demographic difference identified between the delayed and non-delayed patients; however, the delayed group was significantly more likely to have better vision in their non-treated eye (p = 0.0003). A statistically significant difference was found in the change in VA between the delayed and the not-delayed group for eyes with nAMD (p = 0.001) but not for RVO or DMO. For the delayed group, mean CMT increased by 33 and 100 μm, respectively, for nAMD and RVO and decreased by 7.8 μm for DMO. The VA of 89.7% of DMO eyes returned to baseline, compared to 74.6% and 76.9% of nAMD and RVO eyes.

Conclusion

The RCOphth guidance to prioritise intravitreal injections for nAMD over DMO appears appropriate in this cohort but not for RVO. Eyes with nAMD experienced the greatest loss of vision with treatment delay, and nAMD and RVO eyes were less likely to return to baseline on restarting treatment.

Cevik M, Bamford CGG, Ho A (2020) COVID-19 pandemic—a focused review for clinicians. Clin Microbiol Infect 26:842–847. https://doi.org/10.1016/j.cmi.2020.04.023CrossRefPubMedPubMedCentral

The Royal College of Ophthalmologists (2020) Medical retinal management plans during COVID-19. https://www.rcophth.ac.uk/wp-content/uploads/2020/03/Medical-Retinal-Management-Plan-during-COVID-19-UPDATED-300320-1-2.pdf. Accessed 29 Apr 2020

Stone LG, Devenport A, Stratton IM, Talks JS (2020) Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19. Graefe’s Arch Clin Exp Ophthalmol 258:2639–2645. https://doi.org/10.1007/s00417-020-04849-8CrossRef

Luo M, Guo L, Yu M, Wang H (2020) The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public—a systematic review and meta-analysis. Psychiatry Res 291:113190. https://doi.org/10.1016/j.psychres.2020.113190CrossRefPubMedPubMedCentral

Wickham L, Hay G, Hamilton R et al (2020) The impact of COVID policies on acute ophthalmology services—experiences from Moorfields Eye Hospital NHS Foundation Trust. Eye 34:1189–1192. https://doi.org/10.1038/s41433-020-0957-2CrossRefPubMedPubMedCentral

Kim JH, Chang YS, Kim JW (2017) Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina 37:2254–2261. https://doi.org/10.1097/IAE.0000000000001494CrossRefPubMed

Browning DJ, Stewart MW, Lee C (2018) Diabetic macular edema: evidence-based management. Indian J Ophthalmol 66:1736–1750. https://doi.org/10.4103/ijo.IJO_1240_18CrossRefPubMedPubMedCentral

McIntosh RL, Rogers SL, Lim L et al (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117:1113–1123. https://doi.org/10.1016/j.ophtha.2010.01.060CrossRefPubMed

Saleh OA, Jammal H, Alqudah N et al (2020) Clinical experience in the administration of intravitreal injection therapy at a tertiary university hospital in jordan during the covid-19 lockdown. Clin Ophthalmol 24:2473–2480. https://doi.org/10.2147/OPTH.S269179CrossRef

10.

Strata Decision Technology (2020) Analysis: ophthalmology lost more patient volume due to COVID-19 than any other specialty. In: Eyewire. https://eyewire.news/articles/analysis-55-percent-fewer-americans-sought-hospital-care-in-march-april-due-to-covid-19/. Accessed 21 Dec 2020

11.

Borrelli E, Grosso D, Vella G et al (2020) Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let’s be ready for a plausible “rebound effect.” Graefe’s Arch Clin Exp Ophthalmol 258:2655–2660. https://doi.org/10.1007/s00417-020-04858-7CrossRef

12.

Gao X, Obeid A, Aderman CM et al (2019) Loss to follow-up after intravitreal anti–vascular endothelial growth factor injections in patients with diabetic macular edema. Ophthalmol Retin 3:230–236. https://doi.org/10.1016/j.oret.2018.11.002CrossRef

13.

Obeid A, Gao X, Ali FS et al (2018) Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol 136:1251–1259. https://doi.org/10.1001/jamaophthalmol.2018.3578CrossRefPubMedPubMedCentral

14.

Boulanger-Scemama E, Querques G, About F et al (2015) Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol 38:620–627. https://doi.org/10.1016/j.jfo.2014.11.015CrossRefPubMed

15.

Greenlee TE, Wang VY, Kang H et al (2020) Consequences of lapses in treatment with vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci 61:4202–4202. https://doi.org/10.1097/iae.0000000000002888CrossRef

16.

Soares RR, Mellen P, Garrigan H et al (2020) Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor. Ophthalmol Retin 4:134–140. https://doi.org/10.1016/j.oret.2019.07.010CrossRef

17.

Lazić R, Boras I, Vlašić M et al (2010) Anti-VEGF in treatment of central retinal vein occlusion. Coll Antropol 34:69–72PubMed

18.

Rezar S, Eibenberger K, Bühl W et al (2015) Anti-VEGF treatment in branch retinal vein occlusion: A real-world experience over 4 years. Acta Ophthalmol 93:719–725. https://doi.org/10.1111/aos.12772CrossRefPubMed

19.

Weiss M, Sim DA, Herold T et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 38:2293–2300. https://doi.org/10.1097/IAE.0000000000001892CrossRefPubMed

20.

Yalamanchili SP, Maatouk CM, Enwere DU et al (2020) The short-term effect of a single lapse in anti–vascular endothelial growth factor treatment for diabetic macular edema within routine clinical practice. Am J Ophthalmol 219:215–221. https://doi.org/10.1016/j.ajo.2020.06.040CrossRefPubMedPubMedCentral

21.

Guymer RH, Markey CM, McAllister IL et al (2019) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID Study 24-Month Results. Ophthalmology 126:723–734. https://doi.org/10.1016/j.ophtha.2018.11.025CrossRefPubMed

Title: Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity
Authors: Lydia G. Stone
Michael E. Grinton
James S. Talks
Publication date: 01-07-2021
Publisher: Springer Berlin Heidelberg
Keyword: COVID-19
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 7/2021
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-021-05174-4

At a glance: The STEP trials

Springer Medicine

Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2021

Prevalence of age-related macular degeneration among optometric telemedicine users in Spain: a retrospective nationwide population-based study

Persistent macular holes — what is the best strategy for revision?

Short-term outcomes of a modified technique for small-incision scleral-fixated intraocular lens implantation using Gore-Tex sutures

Ring lymphoma: highly indicative ultrasound biomicroscopy findings of ciliary body lymphoma

Outcomes after Descemet membrane endothelial keratoplasty over a period of 7 years at a tertiary referral center: endothelial cell density, central corneal thickness, and visual acuity

Comparability of corneal thickness and opacity depth assessed by OCT and UBM